Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Significant improvement for clinical cancer research in Germany

The National Center for Tumor Diseases will be expanded by four sites

No. 06 | 02/02/2023

The National Center for Tumor Diseases (NCT) is a long-term cooperation between the German Cancer Research Center (DKFZ), university medical centers, and other outstanding research partners at various sites in Germany. On February 2, 2023, the German Federal Ministry of Education and Research (BMBF) has confirmed the NCT expansion with four new sites: Berlin, SouthWest (Tübingen/Stuttgart-Ulm), WERA (Würzburg with partners Erlangen, Regensburg, and Augsburg), and West (Essen/Cologne). With the existing sites in Heidelberg and Dresden, a total of six NCT sites are now cooperating with the DKFZ with the aim of sustainably advancing state-of-the-art clinical cancer research in Germany and thereby improving the treatment outcomes and quality of life of cancer patients.

© NCT/Marius Stark

One goal of the National Decade against Cancer, which was proclaimed by the BMBF in 2019, is to expand the NCT with new sites nationwide. This was preceded by the success of the NCT's two existing pilot sites in Heidelberg and Dresden.

In the fall of 2020, the BMBF selected four new sites for NCT expansion based on the recommendation of an international panel of experts. Subsequently, the DKFZ and the two existing and all new sites developed a comprehensive joint strategic concept and a complementary implementation plan. A large number of leading scientists, oncologists from all disciplines, and patient representatives from all sites were involved in the concept development. A final international review confirmed the joint strategy and its implementation plan. Consequently, the BMBF has given the go-ahead for the establishment of the new sites and the Germany-wide collaboration on the expanded NCT.

The expanded NCT specifically addresses the major current weaknesses of clinical cancer research in the German research landscape. With its focus on innovative clinical trials, the NCT enables new developments from the laboratory to be tested clinically quickly and to the highest standards, thereby making better diagnostic and treatment options available to patients. Special emphasis is placed on personalized oncology, participation of patients as research partners, rapid and fair patient access to advances in cancer research, and the training of future generations of clinical cancer researchers.

The expanded NCT establishes sustainable joint research and cooperation structures, bundles existing national potential and thereby creates synergies that drive the transfer of innovations to patient care, the healthcare system, the economy, and society. The significant investment of the BMBF makes it possible to realize this "one NCT" project.

"The NCT expansion from two to six sites is an outstanding milestone in the National Decade Against Cancer. We are extremely grateful to the BMBF for this generous and long-term investment in the future of cancer research," said Prof. Dr. Michael Baumann, Chairman of the Board of the DKFZ, co-speaker of the NCT Steering Committee and one of the initiators of the NCT expansion. "With the expanded NCT, we are creating an ideal platform to test our own innovations in scientifically driven clinical trials and to compete on an equal footing with the world's leading centers in this field in the future. At the same time, we are giving significantly more patients in Germany access to the advances in cancer research. The NCT is also the first research collaboration in Germany to involve patients as research partners at all levels."

Prof. Dr. Michael Hallek, Director of Clinic I for Internal Medicine at the University Hospital of Cologne and co-spokesperson of the NCT Steering Committee, says: "The NCT expansion means a significant boost for cancer research in Germany. Clinical trials are the key driver for the translation of research results from the laboratory to clinical application. The NCT works closely with the Comprehensive Cancer Centers of the university hospitals, which are funded by German Cancer Aid, and builds on their structures. The NCT expansion enables us to establish a powerful clinical trial landscape and, as one large center ("one NCT"), to accelerate translation while increasing our attractiveness for top international talent."

Markus Wartenberg, Spokesman of the NCT National Patient Advisory Board, says: "Especially the non-commercial science-driven clinical trials, as they are to be conducted at the NCT, have great importance for patients. With the future NCT research culture of "Patients as Research Partners", patients are to be involved in the conception and development of trials at an early stage. In this context, the NCT will also provide opportunities for patients interested in research to educate themselves and exchange ideas with "PEAK - the Patient Academy" and an annual national conference."

When completed, the expanded NCT will be financed with a total of around 100 million euros per year by the BMBF and each site's respective host state in a 90:10 ratio. In addition, the funding provided by the host states will enable the construction of a patient-oriented NCT building at each of the four new sites.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS